- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07693179
Assessment of Prolonged Pain in Infants With Excessive Crying: Contribution of Infrared Thermal Imaging - The NEOTHERM Pilot Study (NEOTHERM)
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Joëlle Provasi, PhD
- Telefonnummer: +33 1 88 12 02 99
- E-post: joelle.provasi@ephe.psl.eu
Studer Kontakt Backup
- Navn: Alizée LORI, MD
- Telefonnummer: +33 01 42 35 61 40
- E-post: alizee.lori@ch-stdenis.fr
Studiesteder
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Frankrike, 75003
- Centre Médico-Psychologique Périnatalité et Petite Enfance Brantôme
-
Ta kontakt med:
- Anne-Sylvie PELLOUX, Doctor
- Telefonnummer: +33 01 48 04 85 56
- E-post: cmp-brantome.75i01@ght94n.fr
-
Saint-Denis, Île-de-France Region, Frankrike, 93200
- Centre Hospitalier de Saint-Denis - Department of Neonatology
-
Ta kontakt med:
- Alizée LORI, Doctor
- Telefonnummer: +33 01 42 35 61 40
- E-post: alizee.lori@ch-stdenis.fr
-
Saint-Denis, Île-de-France Region, Frankrike, 93200
- Centre Hospitalier de Saint-Denis - Department of Perinatal Psychiatry
-
Ta kontakt med:
- Laure QUANTIN, Doctor
- Telefonnummer: +33 01 48 22 19 51
- E-post: laure.quantin@ch-stdenis.fr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Experimental group: excessive crying duration
The study population will comprise 80 infants recruited prospectively from three participating centers. Infants will be enrolled at 2 to 6 weeks post-term in corrected age and reassessed at 10 to 14 weeks post-term in corrected age.
Based on the 7-day parental crying diary completed before the first assessment, infants will be classified into two predefined cohorts: an excessive-crying (EC) cohort and a typical-crying (TC) cohort, with 40 infants planned in each cohort.
Participants in the TC cohort will be matched to participants in the EC cohort according to corrected age at assessment (±1 week), sex when possible, gestational age at birth (±1 week), feeding modality, and maternal parity.
Beskrivelse
Inclusion criteria:
- Infants aged 2 to 6 weeks post-term in corrected age at the first assessment.
- Born at or after 32 weeks' gestational age.
- No known neurological or gastrointestinal disease.
- Written informed consent from the holder(s) of parental authority.
Meeting the criteria for one of the following two cohorts:
- Excessive-crying (EC) cohort: crying for more than 3 hours per day on at least 3 consecutive days during the 7 days preceding the assessment (modified Wessel criteria), together with at least two of the following three protocol-specified Rome IV-related features: crying without an apparent cause, inconsolable crying, and associated signs including agitation, facial flushing, clenched fists, and/or flexed legs.
- Typical-crying (TC) cohort: crying for less than 2 hours per day during the week preceding the assessment.
Infants crying for 2 to 3 hours per day during the week preceding the assessment will not be included in either cohort.
Exclusion criteria:
- Confirmed cerebral lesions identified by ultrasound or magnetic resonance imaging.
- Major congenital or chromosomal abnormalities.
- Growth faltering.
- Birth before 32 weeks' gestational age.
- Holder(s) of parental authority who do not speak French.
- Lack of written informed consent from the holder(s) of parental authority.
- Lack of affiliation with a French social security scheme.
- Any situation falling under specific legal protection provisions under French law.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Excessive-Crying (EC) Cohort
Infants aged 2 to 6 weeks post-term (corrected age) at the first assessment, with crying lasting more than 3 hours per day on at least 3 consecutive days during the 7 days preceding the assessment (modified Wessel criteria). Infants must also meet at least two of the following three protocol-specified Rome IV-related features: crying without an apparent cause, inconsolable crying, and associated signs including agitation, facial flushing, clenched fists, and/or flexed legs. No intervention will be assigned. Participants will undergo the observational assessments specified in the study protocol. |
|
Typical-Crying (TC) Cohort
Infants aged 2 to 6 weeks post-term (corrected age) at the first assessment, with crying lasting less than 2 hours per day during the 7 days preceding the assessment. Participants in the TC cohort will be matched to participants in the EC cohort according to corrected age at assessment (±1 week), sex where possible, gestational age at birth (±1 week), feeding modality, and maternal parity. No intervention will be assigned. Participants will undergo the observational assessments specified in the study protocol. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Association Between Infrared Thermal Imaging Indices and EDIN Total Score
Tidsramme: At baseline (T1) and approximately 8 weeks after baseline (T2)
|
Mean skin temperatures will be extracted from predefined body and facial regions of interest. Infrared thermal imaging indices will include absolute bilateral body temperature differences, central-to-peripheral temperature gradients, and intra-facial temperature gradients calculated relative to the forehead. An absolute temperature difference greater than 0.5°C will be considered an abnormal thermal asymmetry. The EDIN is a behavioral scale assessing facial expression, body movements, sleep, interaction, and consolability. Each item is scored from 0 to 3. Higher scores indicate greater pain- or discomfort-related behaviors; a total score of 5 or higher indicates probable prolonged pain. Concordance between infrared thermal imaging indices and EDIN total scores will be quantified using Spearman rank correlation coefficients at each assessment. Thermal images will be analyzed by an external assessor blinded to the EDIN score and cohort classification. |
At baseline (T1) and approximately 8 weeks after baseline (T2)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Associations Between Hair Cortisol Concentration, Infrared Thermal Imaging Indices, and EDIN Total Score
Tidsramme: At baseline (T1) and approximately 8 weeks after baseline (T2)
|
Hair cortisol concentration will be measured in pg/mg of hair from a small sample collected from the occipital region. Cortisol will be quantified using high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS). Hair cortisol concentration will be investigated as a biomarker of prolonged stress. Spearman correlation coefficients will be calculated between hair cortisol concentration, infrared thermal imaging indices, and EDIN total scores |
At baseline (T1) and approximately 8 weeks after baseline (T2)
|
|
General Movements Assessment Scores and Motor Patterns
Tidsramme: At baseline (T1); approximately 15, 30, and 45 days after baseline; and approximately 8 weeks after baseline (T2)
|
Spontaneous general movements will be recorded with the infant lying supine, wearing only a diaper or onesie, during 2 to 5 minutes of active wakefulness without crying, interaction, a pacifier, or hiccups. Recordings will be independently evaluated by two assessors trained in General Movements Assessment and blinded to cohort classification, EDIN scores, and infrared thermal imaging results. The General Movement Optimality Score-Revised (GMOS-R; maximum score 38) will be used at Visit 1. The Motor Optimality Score- Revised (MOS-R) will be used at Visit 2; scores of 25 to 28 are considered optimal, whereas lower scores indicate less optimal motor organization. Qualitative motor characteristics, including movement quality, variability, fluency, symmetry, posture, and atypical movement patterns, will also be described and compared between cohorts. |
At baseline (T1); approximately 15, 30, and 45 days after baseline; and approximately 8 weeks after baseline (T2)
|
|
Psychomotor Development Assessed Using the Bayley Scales of Infant and Toddler Development, Fourth Edition
Tidsramme: At baseline (T1) and approximately 8 weeks after baseline (T2)
|
Psychomotor development will be assessed using the Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4). Five subtests will be administered: cognitive development, receptive communication, expressive communication, fine motor development, and gross motor development. Raw subtest scores will be converted to scalar and composite scores using the normative tables of the Bayley-4. Higher scores indicate better performance in the assessed developmental domain. Scores will be compared between the EC and TC cohorts. Scoring will be performed by an assessor blinded to cohort classification. |
At baseline (T1) and approximately 8 weeks after baseline (T2)
|
|
Associations Between Early Motor Organization and Prolonged Pain or Stress Indicators
Tidsramme: From baseline (T1) through approximately 8 weeks after baseline (T2)
|
Associations between General Movements characteristics, GMOS-R or MOS scores, Bayley-4 scores, infrared thermal imaging indices, EDIN total scores, and hair cortisol concentrations will be examined using Spearman correlations and exploratory regression analyses.
|
From baseline (T1) through approximately 8 weeks after baseline (T2)
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2025-A00767-42
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .